Pune , Jan. 28, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the radiopharmaceuticals market is operating and is predicted to expand soon. The manufacturers and suppliers involved in the radiopharmaceuticals market are present across various countries in the above-mentioned regions.
Get Sample Copy of This Report @
https://greyviews.com/reports/radiopharmaceuticals-market/465/request-sample
The report provides a detailed understanding of the market segments which have been formed by combining different prospects such as the procedural volume, application, and region. Apart from this, the key driving factors, restraints, potential growth opportunities, and market challenges are also discussed in the below paragraphs.
The significant players operating in the global radiopharmaceuticals market are Mallinckrodt PLC, GE Healthcare (A Fully-Owned Subsidiary of General Electric Company), Cardinal Health, Inc., Bayer AG, Bracco Imaging S.P.A, Lantheus Medical Imaging, Inc., Eczacibasi-Monrol Nuclear Products, Advanced Accelerator Applications S.A., Nordion, Inc. (A Subsidiary of Sterigenics International LLC.), Iba Molecular among other. To achieve a substantial market share in the worldwide radiopharmaceuticals market and strengthen their position, manufacturers are pursuing expansion methods such as current developments, mergers and acquisitions, product innovations, collaborations, and partnerships, joint ventures.
One of the main factors influencing the growth of the nuclear medicine imaging market is an increased understanding of the potential effects of early and timely diagnosis and the related favourable influence in the management and treatment of chronic illnesses. The development of nuclear imaging technologies, notably PET/PET-CT, has helped to expand the field of uses for this modality from oncology to cardiology, neurology, and infection detection. The number of PET and SPECT procedures has significantly increased as a result of these technological advancements. In 2020, there were 2,220,300 PET treatments carried out in the United States, up from 2,200,800 in 2019. The increased volume of procedures was brought on by the growing use of PET scanners. The global increase in acute and chronic diseases like cancer as a result of many factors is one of the main drivers propelling the market's rise. Tumor cells in organs or the entire body can be found using radiopharmaceuticals. Cancer is the second largest cause of mortality worldwide. Another important factor driving market expansion is a renewed focus on improving the state of healthcare facilities and the infrastructure of the sector as a whole.
Enquiry Before Buying This Report @ https://greyviews.com/inquiry/465
Scope of Radiopharmaceuticals Market Report
| Report Metric | Information |
| Study Period | 2022-2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Market Share Unit | USD Billion |
| Segments Covered | Procedural Volume, Application, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle-East and Africa |
| Major Players | Cardinal Health (US), Lantheus Medical Imaging (US), General Electric, Eczacýbaþý-Monrol Nuclear Products (Turkey), Curium (France), Advanced Accelerator Applications (France), Bayer AG (Germany), Bracco Imaging (Italy), JSC Isotope (Russia), Nordion (Canada),NTP Radioisotopes (South Africa), Eckert & Ziegler (Germany), NorthStar Medical Radioisotopes (US), and Braun Melsungen AG (Germany).among other |
Segmentation Analysis
The diagnostic procedures segment is expected to be the fastest-growing segment in 2022.
The procedural volume segment is diagnostic procedures and therapeutic procedures. The diagnostic procedures segment is expected to witness the highest growth rate during the forecast period. When other forms of treatment for depression have failed, TMS machines are routinely utilised. The most effective way to treat depression is by giving patients antidepressant-like drugs because doing so boosts treatment effectiveness while lowering the likelihood of clinically significant side effects.
The oncology segment is expected to be the fastest-growing segment in 2022.
The application segment is an endocrinology, oncology, neurology, cardiology, and others. The oncology segment is expected to witness the highest growth rate during the forecast period. The increased prevalence of cancer and cardiovascular disorders such coronary heart disease and heart failure is helping the market expand. The increasing prevalence of lifestyle disorders, obesity, and tumours brought on by poor behaviours in the elderly are the key factors driving demand for radiopharmaceuticals. Breast, lung, and prostate cancer incidence rates will increase, driving industry growth. The increasing use of nuclear medicine in cardiology and cancer treatment is the primary driver of market expansion. According to the American Cancer Society, the US would see 1.9 million new cases of cancer and 608,570 deaths from cancer in 2021.
Regional Analysis
The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for radiopharmaceuticals include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia.
- The North America region witnessed a major share. Due to an ageing population and poor lifestyle decisions that have led to an increase in cancer and obesity cases, nuclear medicine sales have increased. The development of the nation's radiopharmaceutical industry is anticipated to be boosted by the use of novel radioisotope manufacturing techniques to treat these ailments. According to the American Heart Association, cardiovascular disease claims 17.3 million lives each year. Radiologists benefit from using radiopharmaceuticals for treating a variety of illnesses. The demand for radiopharmaceuticals will increase in the United States due to the development of targeted drugs and sophisticated technology for the treatment of cancer and cardiovascular disease.
Country Analysis
- Germany
Germany's radiopharmaceuticals market size was valued at USD 0.34 billion in 2022 and is expected to reach USD 0.84 billion by 2030, at a CAGR of 12.1% from 2023 to 2030. A big patient population with chronic illnesses like cancer, coronary artery disease, and strokes, a strong healthcare infrastructure in the area, and growing research activities.
- China
China’s radiopharmaceuticals market size was valued at USD 0.35 billion in 2022 and is expected to reach USD 0.88 billion by 2030, at a CAGR of 12.3% from 2023 to 2030. The introduction of new products, acquisitions, distribution agreements, joint ventures, and regional development by local enterprises, particularly in China, are predicted to drive the market for radiopharmaceuticals in the region.
- India
India's radiopharmaceuticals market size was valued at USD 0.27 billion in 2022 and is expected to reach USD 0.67 billion by 2030, at a CAGR of 12.2% from 2023 to 2030. Due to an increase in government initiatives to raise awareness, an increase in medical tourism, an increase in research activities in the area, the presence of significant market players, the availability of vast untapped markets, a large population pool, the presence of well-established infrastructure, an increase in cardiovascular disease cases, and an expanding demand for high-quality healthcare in the region.
Covid-19 Impact
Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries.
Furthermore, the growth of the radiopharmaceuticals market is mainly driven by the rise in technological advancements in healthcare.
Buy Now Full Report @ https://greyviews.com/checkout/465/single_user_license
Contact Us
Rocky Shah
GreyViews
Pune India
Phone: (+44) 162-237-1047
Email: sales@greyviews.com
Browse Related Reports:
Veterinary Hematology Analyzers Market Size By Product Type (Table Top Analyzers (Fully Automatic Analyzers and Semiautomatic Analyzers) and Point of Care Analyzers (Cartridge-Based Analyzers and Direct Sample Based Analyzers), By Analysis Parameter (2-Part WBC Differential, 3-Part WBC Differential, 5-Part WBC Differential, and Others), By End-User (Research institutes, Veterinary hospitals and clinics, Veterinary diagnostic centers, point-of-care testing, inhouse-testing, and others), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/veterinary-hematology-analyzers-market/469
Structural Heart Devices Market Size By Indication (Atrial Septal Defects, Aortic Valvular Disease, Pulmonary Valvular Disease, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Valvular Disease, Patent Ductus Arteriosus, and Others), By Product Type (Heart Valve Devices, Annuloplasty Rings, Occluders and Delivery Systems, Transcatheter Mitral Valve Repair, and Others), By Procedure(Repair and Replacements), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/structural-heart-devices-market/467
Shoulder Arthroplasty Market Size By Indication (Arthritis, Fracture/Dislocation, Rotator Cuff Tear Arthropathy, Hill Sachs Defect, and Others), By Device (Shoulder Arthroplasty Resurfacing Implants, Shoulder Arthroplasty Trauma Devices, and Shoulder Arthroplasty Platform Systems), By Procedure (Partial Shoulder Arthroplasty, Total Shoulder Arthroplasty, Reverse Shoulder Arthroplasty, and Revision Shoulder Arthroplasty), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/shoulder-arthroplasty-market/466
Radiopharmaceuticals Market Size By Procedural Volume (Diagnostic Producers and Therapeutic Procedures), By Application (Endocrinology, Oncology, Neurology, Cardiology, and Others), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/radiopharmaceuticals-market/465
Intrathecal Pumps Market Size By Type (Morphine, Baclofen, Ziconotide, Clonidine, Bupivacaine, and Others), By Application (Pain and Spasticity), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/intrathecal-pumps-market/462
Injection Molding Market Size By Material (Metals, Plastics, and Others), By Technology (Electric, Hydraulic, and Hybrid), By Application (Building & Construction, Packaging, Medical, Consumables & Electronics, Automotive & Transportation, and Others), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/injection-molding-market/461
Influenza Diagnostics Market Size By Test Type (Cell Culture, RIDT, RT-PCR and Others), By End-User (Diagnostic Laboratories, Clinics, Hospitals and Others), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/influenza-diagnostics-market/460
Intrathecal Pumps Market Size By Type (Morphine, Baclofen, Ziconotide, Clonidine, Bupivacaine, and Others), By Application (Pain and Spasticity), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/hemato-oncology-testing-market/458
Embolotherapy Market Size By Disease (Oncology, Peripheral Vascular Diseases and Others), By Embolic Agents (Liquid Embolic Agent, Microspheres, Embolic Coils, Detachable Balloons and Others), By End-User (Ambulatory Surgery Centres, Hospitals & Clinics and Others), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/embolotherapy-market/453
Embolization Coils Market Size By Type (Pushable Coil and Detachable Coil), By Application (Urology, Cardiology, Oncology, Neurology, and Others), By Material (Platinum Tungsten Alloy, Platinum and Platinum & Hydrogel), Regions, Segmentation, and Projection till 2030
https://greyviews.com/reports/embolization-coils-market/452
